The willingness of the agencies involved in the regulation of pharmaceuticals to accept data from newly proposed models for carcinogenicitytesting (eg, transgenic animals, neonatal rodent models, initiation-promotion models) has stimulated international interest in gaining experience and a greater ...
Background and Framework for Collaborative Evaluation Program on Alternative Models for Carcinogenicity Assessment
Toxicologic Pathology, 2001